Fineotex Chemical Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.5K Cr

Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon.

From Fineotex Chemical Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹47.4

Market Cap

₹4.5K Cr

P/E Ratio

36.8

How does Fineotex Chemical Ltd rank in Chemicals & Petrochemicals?

Compare Fineotex Chemical Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Fineotex Chemical Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹314 Cr, net profit ₹44 Cr.

Full financials →

📊 Revenue & Sales Performance

- Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. $90-100 million (Q4 annualized) to $200 million by 2028, accelerating from prior 2030 target (Page 6, 7). - Textiles business will continue organic growth but decrease in revenue percentage due to faster oilfield segment growth (Page 19-20). - Expansions like doubling capacity in Midland and increased R&D investment support growth (Page 18-20). - EBITDA margins targeted to improve to 18-20%, indicating operational leverage alongside revenue growth (Page 14, 10). Overall, Fineotex foresees robust growth driven by oilfield specialty chemicals and strategic acquisitions.

📈 Profitability & Margins

→Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon.
→Q4 FY26 sets a base with INR314 crore revenue, with international revenues rising to 70%.
→EBITDA margin guidance: targeting 18%-20% blended EBITDA, achievable by FY27 or sooner.
→Oil Specialty Chemicals now contribute ~55-60% of revenue—expected to grow faster than textiles.
→CrudeChem (CCT) business expected to scale from ~$100 million annualized (Q4 run rate) to $200 million by 2028, with EBITDA margins near 15%.
→EPS growth aligns with revenue and margin expansion; PAT for FY27 estimated in the range of INR175-185 crore.
→Working capital cycle stable (~79 days), supporting healthy cash flows post-acquisition.
→Strong focus on operational efficiencies and expanding specialty chemical portfolio for sustained profit growth.

🏗️ Capital Expenditure Plans

→Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth.
→Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments.
→The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target.
→There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S. and Middle East markets.
→Fineotex has a subsidiary in UAE (Ras Al Khaimah) with plans to start a plant there, and remains open to acquisitions or tie-ups in the region.
→The company remains cash-rich with no debt, enabling disciplined deployment of cash for strategic and organic growth investments.

💰 Fundraising & Capital Structure

- Fineotex Chemical Limited currently has no debt on its books and is described as a cash-rich company. - Recent acquisitions and capex investments (e.g., $7 million post-acquisition capex for CCT) have been funded internally. - There is no explicit mention of any upcoming or planned fundraising through debt or equity in the call transcript. - The company emphasizes disciplined cash deployment and prefers organic growth and selective inorganic acquisitions funded from internal accruals and cash reserves. - The management highlights a strong financial position enabling focus on growth opportunities without referencing any new equity or debt raising plans. - Any future developments about fundraising, if needed, would likely be communicated transparently to investors via stock exchange disclosures. In summary, Fineotex plans to fund growth from existing cash and internal resources, with no current indication of new debt or equity fundraising.

📋 Order Book & Pipeline

→The Q4 of FY2025-26 is considered the baseline for future growth at CCT (CrudeChem).
→The current order book at CCT is described as "too strong" and robust, indicating healthy pending orders.
→Increasing market demand and strengthened customer trust are driving a growing order pipeline.
→North American market expansion and new opportunities in the Middle East (e.g., Oman) suggest a rising order book.
→With capacity enhancements and technology transfers, CCT expects to sustain and grow its order book significantly in the coming years.

Key Metrics

What Fineotex Chemical Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

NOCIL (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
Indo Borax & Chemicals Ltd (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
Rossari Biotech (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
Pidilite Inds. (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Fineotex Chemical Ltd Q4 FY26 results?

What is Fineotex Chemical Ltd share price analysis?

Fineotex Chemical Ltd currently shows a neutral. The stock trades at a P/E of 36.8 with a market cap of ₹4,501 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fineotex Chemical Ltd planning capital expenditure?

Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth. - Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments. - The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target. - There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S.

Keep Fineotex Chemical Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.